Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Axsome Therapeutics, Inc. (AXSM)

Axsome reports Q2 2026 net product revenue up 46% to $218.4 million; net loss widens

Mixed Impact 3 of 5 earnings Written later

Axsome reported second-quarter 2026 total net product revenue of $218.4 million, up 46% year over year, with AUVELITY contributing $180.3 million. The net loss widened to $51.3 million, or $(0.99) per share, from $48.0 million, or $(0.97) per share, a year earlier, as selling, general and administrative expenses rose to $208.1 million. Revenue growth and the larger loss point in opposite directions for shareholders.

Key points

  • Total net product revenue was $218.4 million, up from $150.0 million; AUVELITY net product sales were $180.3 million, up 51%.
  • Net loss was $51.3 million, or $(0.99) per share, versus $48.0 million, or $(0.97) per share, in the second quarter of 2025.
  • SG&A expenses rose to $208.1 million from $130.3 million, primarily reflecting AUVELITY commercialization, including the sales force expansion and Alzheimer's disease agitation launch.
  • Cash and cash equivalents totaled $319.9 million at June 30, 2026; the company believes this is sufficient to fund operations into cash flow positivity.

The filing

CompanyAxsome Therapeutics, Inc. (AXSM)
Form8-K, current report
Filed with the SECAug 10, 2026, 7:05 AM ET
Accession number0001193125-26-341206

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.